1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This grant aims to advance gene-based therapies for ultra-rare neurological and neuromuscular disorders.
This initiative focuses on IND-enabling studies and supports the development of innovative therapeutics with proven biological rationale.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Agency: National Institutes of Health Assistance Listings: 93.
859 -- Biomedical Research and Research Training Last Updated: August 20, 2026 View version history on Grants. gov The Institutional Development Award (IDeA) program develops biomedical research capacity in states that have historically received low levels of NIH funding (IDeA states).
The IDeA Clinical & Translational Research (CTR) program supports two programmatic tracks to build clinical and translational (C&T) research capacity to enable research on diseases and health challenges prevalent in IDeA states. IDeA CTR Development (CTR-D) awards focus on C&T research workforce development and infrastructure enhancement at health research organizations with limited clinical research capacity in IDeA states....
IDeA CTR Network (CTR-N) awards support statewide (or multi-state) networks of health research organizations to expand existing infrastructure, develop the research workforce to enhance the network organization's ability to design and implement competitive C&T research programs, and coordinate clinical research activities state-wide and/or across IDeA states.
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information.
In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.
Public and state institutions of higher education Private institutions of higher education Independent school districts Federally recognized Native American tribal governments City or township governments Special district governments Public and Indian housing authorities Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) For-profit organizations other than small businesses Eligibility Criteria for Lead and Partner OrganizationsEvery organization in the application must be either a Lead or a Partner–no organization can be both.
Every organization in the application must be in an IDeA-eligible state. There are strict limits to avoid overlap:Each IDeA-eligible state can only have one active IDeA-CTR-type (IDeA-CTR, CTR-N, or CTR-D) award at a time. An organization can only be involved in one IDeA-CTR-type award at a time.
Organizations may not serve as a lead, partner or otherwise participate with an active Clinical and Translational Science Award (CTSA). Organizations must meet all eligibility rules at the time of application submission and award. Additional Eligibility Criteria for Lead OrganizationsTo apply as the lead, the organization must:Already have externally-funded clinical and translational (C&T) research.
Additional Eligibility Criteria for Partner OrganizationsTo participate as a partner, the organization mustBe in the same state or multi-state region as the lead organization. Note:Active awards include awards in no-cost extension (NCE). An organization that currently leads an active IDeA-CTR-type award may submit a new application if substantial changes to the CTR are proposed.
If the new application is funded, the current award will be administratively ended before the new award begins. Grantor contact information NIGMS_IDeA-CTR@mail. nih.
gov NIGMS_IDeA-CTR@mail. nih. gov NIGMS_IDeA-CTR@mail.
nih. gov File name Description Last updated PAR-27-056-Revised-Full-Announcement. html PAR-27-056-Revised-Full-Announcement.
html Aug 20, 2026 11:39 AM UTC Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Not specified, but generally targets institutions in IDeA states. Confirm the full requirements in the official notice before applying.
Applications for Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) are due May 31, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) is funded by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Focused Technology Research and Development (R01 Clinical Trial Not Allowed) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) supports projects relevant to the NIGMS mission that focus solely on the development of technologies with the potential to enable the acquisition of biomedical knowledge. The project outcome is a working prototype of the technology.
R21 Exploratory Technology Development is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This program supports exploratory technology development projects relevant to the NIGMS mission. It is suitable for novel, high-risk projects, and preliminary data is not required. The project outcome is a proof of concept study.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article